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Abstract
The synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN/CD437) appears to possess an
apoptotic activity superior to classical retinoids in vitro as in vivo. Numerous studies have shown that CD437-induced apoptosis is independent
of its nuclear receptor activity, suggesting that CD437 might have a unique mechanism of action. The purpose of this study was to compare
CD437- and all-trans retinoic acid (atRA)-induced cell death. CD437 provoked a rapid apoptotic phenotype immediately followed by
secondary necrosis in RPMI 8226, U266 and L363 human myeloma cell lines. Nuclear apoptotic features were observed upon both CD437 and
atRA treatments. In contrast, membrane blebbing and the subsequent formation of apoptotic bodies, a classical apoptotic event, was only
observed upon atRA treatment. In addition, CD437, contrary to atRA, was unable to induce tissue transglutaminase (tTG), an intracellular
enzyme involved in the formation of cross-linked protein polymers contributing to apoptotic morphological changes. Taken together, these
data suggest that CD437 induces rapid but incomplete apoptotic phenotype in human myeloma cells.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Vitamin A-derived retinoids including all-trans retinoic
acid (atRA) play a fundamental role in regulating cellular
growth. The atRA has been reported to inhibit the prolifer-
ation [1–3], and induce apoptosis, of myeloma cells [2–4].
Unfortunately, atRA is not a potent therapeutic agent for
myeloma patients [5], and new therapeutic approaches are
needed. Synthetic retinoids, specific for different retinoid
receptor types (RAR or RXR) and subtypes (a,h,g), have
been developed. Among them, 6-[3-(1-adamantyl)-4-hydrox-
yphenyl]-2-naphthalene carboxylic acid (AHPN/CD437),
first described as a RARg selective retinoid [6], promotes
apoptosis in vitro and in vivo [7–13] in a wide variety of
tumor cell lines, including atRA-resistant cells [7,9–12] as
well as RARg-negative cells [7,8]. Consequently, the effects
of CD437 cannot solely be related to its RARg selectivity but
must be mediated by other, possibly unique, pro-apoptotic
mechanisms. Several reports have highlighted that CD437
interferes with the execution phase of apoptosis via both
caspase-dependent and -independent pathways [7–13].
Apoptosis is a well-controlled type of cell death leading to
specific biological and morphological changes. Apoptosis
differs from necrosis in that cellular shrinkage and chromatin
condensation occurs, followed by formation of membrane-
bound vesicles containing fragmented nuclear DNA and
intact organelles inside. During the later stages of apoptosis,
these apoptotic bodies are cleared by phagocytosis. Tissue
transglutaminase (tTG), an enzyme catalyzing the formation
of cross-links between polypeptide chains, is upregulated in
many cells undergoing apoptosis. In fact, tTG seems to be
implicated in the formation of apoptotic bodies and has been
suggested to play an important role in apoptosis (reviewed in
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Ref. [14]). We have previously demonstrated that atRA
induces tTG and apoptosis in the RPMI 8226 cell line by a
mechanism involving ligand-dependent activation of both
the RAR and RXR receptors [2], and that some morpho-
logical features of atRA-induced apoptosis can be negatively
regulated without impeding cell death [3]. Based on the
above findings, we have compared the apoptotic morpho-
logical changes and tTG expression in CD437- and atRA-
treated RPMI 8226 cells.
2. Materials and methods
2.1. Retinoids and antibodies
The atRA and CD437 were purchased from Sigma (St.
Louis, MO, USA) and obtained from CIRD Galderma
(Sophia Antipolis, France), respectively. Mouse monoclonal
anti-tTG and rabbit polyclonal anti-lamin B were gifts from
Dr. Birckbichler (USA) and Dr. Courvalin (France), respec-
tively. Fluorescein (Biosys, France) or peroxidase (Pierce,
USA)-conjugatedanti-IgGwereusedas secondaryantibodies.
2.2. Cell line, cell viability and treatments
Culture and treatment of RPMI 8226 (CCL-155, ATCC),
U266 (TIB-196, ATCC) and L363 (ACC49, DSMZ) human
myeloma cells were performed as previously described [2,3].
2.3. Flow cytometric detection of apoptosis
The frequency of hypoploid cells was assessed cyto-
fluorometrically by studying the cell cycle distribution as
previously described [8].
2.4. Morphological and immunofluorescence studies
These assays have been previously described [2,3].
2.5. Tissue transglutaminase mRNA detection and activity
measurement
Detection of tTG mRNA expression by reverse tran-
scriptase–polymerase chain reaction (RT-PCR) assay, and
tTG activity by determination of Ca2 +-dependent incorpo-
ration of [3H]putrescine into N,NV-dimethylated casein, were
performed as depicted in Joseph et al. [2].
3. Results and discussion
3.1. CD437 induces rapid apoptosis, followed by necrosis
in RPMI 8226
CD437 and atRA were compared for their ability to
reduce viability and to induce nuclear apoptosis in RPMI
8226 (Fig. 1). We performed a time course analysis of the
decreased viability of CD437- and atRA-treated cells in
comparison to untreated control cells (Fig. 1A). Cell via-
bility was determined using the trypan blue exclusion test.
atRA induced slow but progressive loss of viability. Fifty
percent of cells were dead after 120 h of treatment. In
contrast, CD437-treated cells rapidly lost viability; greater
than f 90% of the cells were dead after only 24 h of
treatment. Whereas both viable cells and some apoptotic
cells (early apoptosis) are detected by trypan blue staining
exclusion, apoptotic cells can be precisely assayed by
propidium iodide staining and flow cytometry (Fig. 1B
and C). CD437 treatment resulted in rapid apparition of
hypoploid cells (Fig. 1B), while induction of apoptotic cells
by atRA occurred much slower (>72 h), reaching a max-
imum after 6 days (Fig. 1C). Approximately the same
amount (30%) of apoptotic cells was observed after
CD437 and atRA addition at 6 h and 6 days, respectively
(Fig. 1B and C). However, after long-time exposure (24 h),
the morphology of most of CD437-treated cells no longer
looked apoptotic but presented typical signs of secondary
necrosis, that is, cytoplasmic swelling and membrane dis-
ruption (data not shown). These results suggest that in
comparison to atRA, CD437 induces rapid apoptosis,
immediately followed (within 24 h) by a necrotic pheno-
type.
3.2. CD437 induces an incomplete apoptotic response
The morphology of RPMI 8226 cells treated with either
CD437 or atRA were compared after MGG staining (Fig.
1D, left panel) and terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP nick end labeling (TUNEL) staining
(Fig. 1D, right panel). Six days after induction, atRA-treated
cells showed typical morphological features of apoptosis,
including condensation and fragmentation of the nucleus as
well as the presence of numerous apoptotic bodies (Fig. 1D).
In contrast, CD437-induced apoptotic cells were character-
ized by a nearly complete absence of apoptotic bodies
formation. The formation of DNA strand breaks, as revealed
by the TUNEL method (Fig. 1D, right panel), confirmed the
apoptotic nature of both CD437- and atRA-treated cells.
3.3. The particular effect of CD437 is observed in other
myeloma cell lines
The rapid induction of cell death and the incomplete
morphological features of apoptosis observed upon CD437
treatment were also observed in U266 and L363 cells, two
additional myeloma cell lines (Fig. 2). RPMI 8226, U266
and L363 cells were treated with CD437 or atRA, and
apoptotic cells were counted after MGG staining. In each
cell line, CD437 treatment induced 22–35% of the cells to
exhibit typical nuclear morphological features of apoptosis
(Fig. 2A and B). In contrast, atRA treatment resulted only in
1–3% of cells with an apoptotic morphology (Fig. 2A and
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data not shown). As in RPMI 8226 cells, CD437-induced
apoptotic U266 and L363 cells were characterized by a near
absence of apoptotic bodies formation (Fig. 2B).
3.4. CD437, like atRA, provokes nuclear lamin B
reorganization
Nuclear breakdown leading to the formation of apop-
totic bodies has been postulated to involve degradation of
nuclear structural proteins, such as lamins B [15]. We
investigated nuclear lamin B distribution by immunofluor-
escence microscopy 6 h after the cells were treated with
CD437 or atRA (Fig. 3A). Control cells displayed a
regular lamin B staining of the nucleus. In the apoptotic
cell population obtained after CD437 or atRA exposure,
lamin B was distributed mainly at the periphery of the
nucleus, surrounding chromatin, and was even found dis-
persed in the cytoplasm. These results indicated the dis-
assembly of lamins during both CD437- and atRA-induced
apoptosis. Lamin B is cleaved by proteolysis in a f 45
kDa fragment during apoptosis [15,16]. The typical pro-
teolytic fragment was detected by Western blot in lysates
from CD437- and atRA-treated cells, whereas a 66-kDa
signal corresponding to native lamin B was revealed in
untreated cells (data not shown). Thus, CD437 as well as
atRA induce nuclear disassembly and lamin B degradation
in RPMI 8226 cells.
3.5. CD437 is unable to induce tTG in apoptotic cells
Because a high expression of tTG is correlated with the
presence of apoptotic bodies, we next evaluated the induc-
tion of tTG at the level of mRNA, protein expression and
enzymatic activity in retinoid-treated cells (Fig. 3B–D). Six
hours after atRA exposure, RT-PCR assay revealed a strong
induction of tTG mRNA in RPMI 8226 [2] (Fig. 3B).
Fig. 1. Time courses of loss of cell viability and apoptosis after treatment with CD437 and atRA in RPMI 8226 cells. (A) Effect of CD437 (1 AM) and atRA
(1 AM) on RPMI 8226 cell viability. At indicated times, viable cells were determined by direct counting using the trypan blue exclusion test. Data represent
the percentage of viable cells in retinoid-treated populations in comparison to untreated cells. Data represent the mean of five independent experiments; S.D.s
were less than 10%. Time-dependent induction of apoptosis by CD437 (1 AM) (B) and atRA (1 AM) (C) in RPMI 8226 cells. Nuclear apoptosis (referred to
as hypoploid cells or cells in sub-G1) was assessed by cytofluorometric analysis of propidium iodide-stained, permeabilized RPMI 8226. Data (XF S.D.) are
representative of four independent experiments. (D) May-Gru¨nwald Giemsa (MGG) staining (left panel) and TUNEL staining (right panel) at 6 h post-
CD437 (1 AM) induction or at day 6 post-atRA (1 AM) treatment. Representative apoptotic cells are indicated by arrows; apoptotic bodies (ab) are also
indicated. Isolated nucleus (*) is indicative of lysed cell.
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Indeed, the expected amplification product was clearly
detected at 20 cycles in atRA-treated cells as compared to
control cells. In contrast, in CD437-treated cells, a very low
induction was observed and the PCR product was only
detected after 25 cycles of amplification. Immunofluores-
cence studies confirmed a high expression of tTG in atRA-
treated cells with the fluorescent signal within apoptotic
bodies, whereas the signal strength in CD437-treated cells
was comparable to the one observed in untreated cells (Fig.
3C). Finally, we assayed tTG enzymatic activity (Fig. 3D).
CD437 was unable to induce tTG activity in RPMI 8226
cells, whereas atRA treatment induced a 20-fold increase in
tTG activity. The slight mRNA expression induced by
CD437 (Fig. 3B, 25-cycle PCR) was similar to the one
observed upon treatment with other synthetic retinoids,
selective for the different RAR subtypes. Similar treatment
Fig. 2. Comparative studies of apoptosis after treatment by CD437 and atRA in RPMI 8226, U266 and L363 cells. (A) Effect of CD437 (1 AM) and atRA (1 AM)
on RPMI 8226, U266 and L363 myeloma cells. After 6 h of incubation, apoptotic cells were counted after May-Gru¨nwald Giemsa staining. Data represent the
percentage of apoptotic cells in retinoid-treated and untreated cell populations. Data represent the mean of three independent experiments; S.D.s were less than
10%. (B) May-Gru¨nwald Giemsa staining of U266 cells (left panel) and L363 cells (right panel) at 6 h post-CD437 treatment (1 AM) in comparison to untreated
control cells. Representative apoptotic cells are indicated by arrows.
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with these synthetic retinoids did not induce any detectable
enzymatic activity (data not shown). These results suggest
that CD437, in contrast to atRA, does not induce tTG
expression in RPMI 8226 cells.
3.6. Concluding remarks
In the present paper, we studied the apparent induction of
an apoptotic response in myeloma cells exposed to CD437
and atRA. Our results demonstrate that CD437 induces
some apoptotic-like responses that differ fundamentally
from bona fide apoptosis induced by atRA.
First, CD437 induces rapid and massive pre-apoptotic
responses immediately followed by secondary necrosis.
This contrasts significantly with the slow time course of
atRA-induced apoptosis, which requires several days to
occur. The fast induction of apoptosis in CD437-treated
cells has been observed in multiple cell types, including
multiple myeloma, leukemia and acute promyelocytic leu-
kemia cell lines [7–13]. Overall, these variations are con-
sistent with the existence of different apoptotic pathways
triggered by CD437 and atRA. Indeed, whereas we have
demonstrated that atRA-induced apoptosis depends on ret-
inoic acid nuclear receptors in RPMI 8226 cells [2], CD437
triggers apoptosis via a nucleus-independent pathway [8].
Moreover, we previously demonstrated the pivotal role of
mitochondria in CD437-induced apoptosis and have estab-
lished that CD437 can act directly on these organelles
[8,17].
Here we show that CD437, in contrast to atRA, is unable
to promote the formation of apoptotic bodies and induction
of tTG activity. The atRA is a pan-RAR agonist which is
Fig. 3. Lamin B and tissue transglutaminase detection in CD437- or atRA-treated RPMI 8226 cells. (A) Indirect immunofluorescence detection of lamin B in
RPMI 8226. Untreated control cells (left) and cells treated with either 1 AM atRA for 6 days (right) or 1 AM CD437 for 6 h (middle) (magnification,  1000).
Results are representative of three independent experiments. (B) Induction of tTG mRNA in RPMI 8226 cells. Cells were cultivated for 6 h with 1 AM CD437
or 1 AM atRA. Total RNA (1 Ag) was submitted to RT and PCR for 15, 20, 25 and 30 cycles, using primers pair for tTG (M55153): upper primer 5V-
CAGTTCCAGTTCGTGCCATCA-3Vand lower primer 5V-ATGCCTGTCTCCTCCTTCTCG -3Vand for h actin (X00351): upper primer 5V-ATCATGTTTGA-
GACCTTCAA-3Vand lower primer 5V-CATCTCTTGCTCGAAGTCCA-3V. PCR products were resolved on 2% agarose gel and revealed by Southern blot
using as a probe, internal primers for amplified sequence of h actin 5V-GACCTGGCTGGGCCGGACCTGACTGACTAC-3Vand tTG 5V-ATCACCCA-
CACCTACAAATACCCAGAG-3V. (C) Indirect immunofluorescence detection of tissue transglutaminase in RPMI 8226. Untreated control cells (left) and cells
treated with either 1 AM atRA for 6 days (right) or 1 AM CD437 for 6 h (middle) (magnification,  1000). Results are representative of three independent
experiments. (D) Tissue transglutaminase activity in RPMI 8226 cells treated with atRA or CD437. Specific transglutaminase activity (corresponding to 1 pmol
of [3H] putrescin incorporated in N,NV-methylcasein/min/mg of cell proteins at 30 jC) was analyzed in cells treated for 2 days with atRA or for 6 h with
CD437. Data (XF S.D.) are representative of four independent experiments.
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able to induce tTG in most cellular models [2,18]. We have
demonstrated that in RPMI 8226 cells which express all
retinoid receptors, induction of tTG expression required the
activation of both the RAR and the RXR pathways [2].
Therefore, the absence of tTG induction after exposure to
the RARg specific retinoid CD437 is likely due to the lack
of synergic activation of the RXR pathway.
Although tTG expression is not obligatorily coupled to
apoptosis, the presence and activity of the enzyme has been
shown to correlate with increased apoptotic cells in numer-
ous cell death models. The activation of tTG leads to the
assembly of intracellular cross-linked protein polymers
contributing to morphological changes occurring in cells
undergoing apoptosis. tTG-dependent protein polymeriza-
tion stabilizes apoptotic cells impeding the lysis of the
plasma membrane and the subsequent release of cell con-
tents into surrounding tissues [19]. We previously demon-
strated that after atRA treatment, tTG accumulated mainly
in apoptotic bodies [2]. Thus, tTG expression could be
related to the formation of apoptotic bodies. In contrast,
the absence of tTG induction after CD437 treatment could
be responsible, at least in part, for the rapid onset of necrotic
processes without apoptotic bodies formation. Taken
together, our results show that CD437 triggers rapid but
morphologically incomplete apoptosis in myeloma cells and
suggest a molecular explanation of this phenomenon.
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